<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIM: To assess the 54-week efficacy of initial combination therapy with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi>, compared with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> monotherapy, and to assess safety in these groups during the 30 weeks after the dosage of <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> was increased from 30 to 45 mg/day, in drug-na√ève patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> and inadequate glycaemic control [<z:chebi fb="34" ids="35143">haemoglobin</z:chebi> A1c (HbA1c) 8-12%] </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: Following a 24-week, randomized, double-blind, parallel-group study (<z:chebi fb="0" ids="40237">Sitagliptin</z:chebi> Protocol 064, Clinicaltrials.gov: NCT00397631; Yoon KH, Shockey GR, Teng R et al </plain></SENT>
<SENT sid="2" pm="."><plain>Effect of initial combination therapy with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi>, a dipeptidyl peptidase-4 inhibitor, and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> on glycaemic control and measures of beta-cell function in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Int J Clin Pract 2011; 65: 154-164) in which patients were treated with the combination of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> 100 mg/day and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> 30 mg/day or monotherapy with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> 30 mg/day, patients entered a 30-week extension study </plain></SENT>
<SENT sid="4" pm="."><plain>In the extension study, the <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> dose was increased from 30 to 45 mg/day in both groups </plain></SENT>
<SENT sid="5" pm="."><plain>Depending upon treatment allocation, patients took one tablet of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> 100 mg or matching placebo daily </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="8228">Pioglitazone</z:chebi> was administered in an open-label fashion as a single 45-mg tablet taken once daily </plain></SENT>
<SENT sid="7" pm="."><plain>Patients not meeting specific glycaemic goals in the extension study were rescued with <z:chebi fb="0" ids="6801">metformin</z:chebi> therapy </plain></SENT>
<SENT sid="8" pm="."><plain>Efficacy and safety results for the extension study excluded data after initiation of rescue therapy </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS: Of the 520 patients initially randomized, 446 completed the base study and, of these, 317 entered the extension </plain></SENT>
<SENT sid="10" pm="."><plain>In this extension study cohort, the mean reductions from baseline in HbA1c and fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG) at the end of the base study (week 24) were -2.5% and -62.1 mg/dl with the combination of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> 100 mg and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> 30 mg versus -1.9% and -48.7 mg/dl with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> monotherapy </plain></SENT>
<SENT sid="11" pm="."><plain>At the end of the extension study (week 54), the mean reduction in <z:chebi fb="34" ids="35143">haemoglobin</z:chebi> A1c (HbA1c) was -2.4% with the combination of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> 100 mg and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> 45 mg versus -1.9% with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> monotherapy [between-group difference (95% CI) = -0.5% (-0.8, -0.3)] and the mean reduction in FPG was -61.3 mg/dl versus -52.8 mg/dl, respectively [between-group difference (95% CI) = -8.5 mg/dl (-16.3, -0.7)] </plain></SENT>
<SENT sid="12" pm="."><plain>Safety and tolerability of initial treatment with the combination of <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> monotherapy were similar </plain></SENT>
<SENT sid="13" pm="."><plain>As expected, increases in body weight from baseline were observed in both treatment groups at week 54: 4.8 and 4.1 kg in the combination and monotherapy groups, respectively [between-group difference (95% CI) = 0.7 kg (-0.7, 2.1)] </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSION: In this study, initial combination therapy with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> 100 mg and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> 30 mg increased to 45 mg after 24 weeks led to a substantial and durable incremental improvement in glycaemic control compared with initial treatment with <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> monotherapy during a 54-week treatment period </plain></SENT>
<SENT sid="15" pm="."><plain>Both initial combination therapy with <z:chebi fb="0" ids="40237">sitagliptin</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> monotherapy were generally well tolerated (Clinicaltrials.gov: NCT01028391) </plain></SENT>
</text></document>